Trial Profile
A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms ABSORB-III; ABSORB-RCT
- Sponsors Abbott Vascular
- 25 Sep 2019 Results assessing five-year follow-up of ABSORB-III trial, published in the Circulation.
- 12 Jun 2019 Status changed from active, no longer recruiting to completed.
- 07 Nov 2018 Planned End Date changed from 1 Sep 2021 to 1 Apr 2019.